Literature DB >> 31087526

The genetic aetiology of retinal degeneration in children in Finland - new founder mutations identified.

Kristiina Avela1, Riitta Salonen-Kajander2, Arja Laitinen3, Simon Ramsden4, Stephanie Barton4, Sirkka-Liisa Rudanko5,6.   

Abstract

PURPOSE: To study the genetic aetiology and phenotypes of retinal degeneration (RD) in Finnish children born during 1993-2009.
METHODS: Children with retinal degeneration (N = 68) were investigated during 2012-2014 with a targeted gene analysis or a next-generation sequencing (NGS) based gene panel. Also, a full clinical ophthalmological examination was performed.
RESULTS: The cohort covered 44% (68/153) of the Finnish children with inherited RD born 1993-2009. X-linked retinoschisis, retinitis pigmentosa, Leber congenital amaurosis and cone-rod dystrophy were the most common clinical diagnoses in the study group. Pathogenic mutations were found in 17 retinal genes. The molecular genetic aetiology was identified in 77% of the patients (in 77% of the families) analysed by NGS method. Several founder mutations were detected including three novel founder mutations c.148delG in TULP1, c.2314C>R (p.Gln772Ter) in RPGRIP1 and c.533G>A (Trp178Ter) in TYR. We also confirmed the previous tentative finding of c.2944 + 1delG in GYCU2D being the most frequent cause of Leber congenital amaurosis (LCA) in Finland.
CONCLUSIONS: Globally, RD is genetically heterogeneous with over 260 disease genes reported so far. This was shown not to be the case in Finland, where the genetic aetiology of RD is caused by a small group of genes, due to several founder mutations that are enriched in the population. We found that X-chromosomal retinoschisis constitutes the major group in Finnish paediatric RD population and is almost exclusively caused by two founder mutations. Several other founder mutations were detected including three novel founder mutations. All in all, the genetic aetiology of 77% of families was identified which is higher than previously reported from other populations, likely due to the specific genomic constitution of the Finns.
© 2019 Acta Ophthalmologica Scandinavica Foundation. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  blindness; founder mutation; molecular genetic aetiology; next-generation sequencing; paediatric retinal degeneration; visual impairment

Mesh:

Substances:

Year:  2019        PMID: 31087526     DOI: 10.1111/aos.14128

Source DB:  PubMed          Journal:  Acta Ophthalmol        ISSN: 1755-375X            Impact factor:   3.761


  4 in total

1.  PRPH2 mutation update: In silico assessment of 245 reported and 7 novel variants in patients with retinal disease.

Authors:  Manon H C A Peeters; Mubeen Khan; Anoek A M B Rooijakkers; Timo Mulders; Lonneke Haer-Wigman; Camiel J F Boon; Caroline C W Klaver; L Ingeborgh van den Born; Carel B Hoyng; Frans P M Cremers; Anneke I den Hollander; Claire-Marie Dhaenens; Rob W J Collin
Journal:  Hum Mutat       Date:  2021-09-20       Impact factor: 4.700

2.  Genetic Basis of Inherited Retinal Disease in a Molecularly Characterized Cohort of More Than 3000 Families from the United Kingdom.

Authors:  Nikolas Pontikos; Gavin Arno; Neringa Jurkute; Elena Schiff; Rola Ba-Abbad; Samantha Malka; Ainoa Gimenez; Michalis Georgiou; Genevieve Wright; Monica Armengol; Hannah Knight; Menachem Katz; Mariya Moosajee; Patrick Yu-Wai-Man; Anthony T Moore; Michel Michaelides; Andrew R Webster; Omar A Mahroo
Journal:  Ophthalmology       Date:  2020-04-16       Impact factor: 12.079

Review 3.  Inherited Retinal Diseases Due to RPE65 Variants: From Genetic Diagnostic Management to Therapy.

Authors:  Manar Aoun; Ilaria Passerini; Pietro Chiurazzi; Marianthi Karali; Irene De Rienzo; Giovanna Sartor; Vittoria Murro; Natalia Filimonova; Marco Seri; Sandro Banfi
Journal:  Int J Mol Sci       Date:  2021-07-05       Impact factor: 5.923

Review 4.  Next-Generation Sequencing Applications for Inherited Retinal Diseases.

Authors:  Adrian Dockery; Laura Whelan; Pete Humphries; G Jane Farrar
Journal:  Int J Mol Sci       Date:  2021-05-26       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.